Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat substance abuse disorders, psychosis, infections, cancer, and dementia.

Novo Nordisk’s NVO shares lost 5.3% on Friday after Medicare issued a press release selecting the company’s popular ...

The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...

Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.

Medicare announced plans to negotiate lower prices for 15 costly drugs, including Ozempic, Wegovy, and Trelegy Ellipta, ...

Meena Seshamani’s Medicare swan song ended on a note of bravura: the announcement that 15 costly drugs, including Novo ...

Weight loss medications Ozempic and Wegovy, in particular, have been scrutinized for their high out-of-pocket costs.

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...

Novo Nordisk A/S (NYSE:NVO), a multinational pharmaceutical company, saw its share prices on Friday retreat by 5.27 percent ...

The U.S. Centers for Medicare and Medicaid Services released its list of drugs covered under Medicare Part D selected for the ...

In the final days of the Biden administration, the U.S. Department of Health and Human Services’ Centers for Medicare and ...